

Strong growth outperformance, margin revival

Auto & Auto Ancillaries ▶ Result Update ▶ August 03, 2025

CMP (Rs): 431 | TP (Rs): 575

Pricol logged a strong Q1, with consol revenue up 44% YoY (also aided by 3M of P3L consolidation vs 2M in Q4FY25) and EBITDAM rising by 60bps QoQ to 11% (ex-P3L, revenue growth stood at 11% with a sharp rise in EBITDAM to 12.3% vs 11.5% in Q4). Core-revenue outperformance against the underlying 2W industry production accelerated to 11% vs 2%/3% in Q4/Q3. Pricol targets continued outperformance vs the underlying industry, on premiumization-led content growth (eg digitization in clusters, new order wins) and new product launches/portfolio expansion (aided by strategic alliances/M&A). The mgmt guides to a healthy single digit margin at P3L, amid initiatives underway toward revenue/margin expansion at P3L as well as at its core operations. We continue to favor Pricol (refer to our note [Targets 3x revenue by FY30; rare earth crunch to hit near term](#)), on further improvement in its competitive positioning in a fast-premiumizing product category (clusters), apart from optionalities of expansion into more components backed by order wins (eg disc brakes launched in Q2; mass production for a strategic customer to start from Q4). Our estimates are unchanged; maintain BUY with TP of Rs575 at 24x Jun-27E PER.

Strong revenue and margin performance; underlying core margins on the rise

Consol revenue was up 44% (13.5% QoQ) at Rs8.9bn with core-revenue (ex-P3L) up 11% YoY. Consol reported EBITDA grew 23% YoY (23% QoQ) to Rs990mn, with EBITDAM rising by 60bps QoQ to 11.1% led by 130bps/20bps reduction in staff costs/opex and partially offset by 80bps gross margin contraction. EBITDAM of the core-business (ex-P3L) also rose, by 75bps QoQ to 12.3%. Consol PAT stood at Rs499mn, up ~10% YoY.

Earnings Call KTAs

1) Pricol aims to continue outpacing the underlying end-user industry (core revenue outperformance vs 2W industry production at 11% in Q1 vs 3%/2% in Q3/Q4FY), aided by new product launches/premiumization-led content growth (value growth beats volume growth) despite ongoing 'rare earth' (REE)-related headwinds. 2) Q1FY26 was muted for the industry, largely due to REE shortages; the mgmt expects headwinds to persist in Q2 and anticipates a more stable production from Q3; Pricol implementing multiple measures for mitigating this issue. 3) Disc brakes launched in Q2, albeit in a limited manner; mass production for a major strategic 2W customer to begin from Jan-26; upcoming ABS regulations seen supporting growth here. 4) Pricol's TLA with Italy-based Domino, for handlebar aggregates (switches, throttles, levers), was at the behest of certain customers; the mgmt expects revenue contribution to start in 12-15M; products for India and SE Asia. 5) P3L posted revenue of Rs2.05bn with ~7% EBITDAM in Q1FY26 (vs Rs1.7bn, 5% in Q1FY25); Pricol has initiated measures to support revenue/margin expansion, incl value-accretive products (engineered/precision plastic components), cost plans, and leveraging Pricol's clientele. 6) Efforts underway to backward integrate/localize displays; progress expected over next 4 quarters; per the mgmt, complete de-risking from China is unfeasible. 7) Pricol plans capex of Rs5bn over next 3Y, of which Rs2.5-3bn is at P3L; 20-22% incremental revenue can be generated from existing capacities.

Target Price – 12M	Jun-26
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	33.4


Stock Data	PRICOL IN
52-week High (Rs)	599
52-week Low (Rs)	368
Shares outstanding (mn)	121.9
Market-cap (Rs bn)	53
Market-cap (USD mn)	600
Net-debt, FY26E (Rs mn)	(137.8)
ADTV-3M (mn shares)	0
ADTV-3M (Rs mn)	112.1
ADTV-3M (USD mn)	1.3
Free float (%)	61.5
Nifty-50	24,565.3
INR/USD	87.5

Shareholding, Jun-25

Promoters (%)	38.5
FPIs/MFs (%)	16.1/15.5

Price Performance

(%)	1M	3M	12M
Absolute	(5.1)	(1.6)	(15.6)
Rel. to Nifty	(1.3)	(2.5)	(14.1)

1-Year share price trend (Rs)**Pricol: Financial Snapshot (Consolidated)**

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	22,718	26,919	37,499	42,296	48,099
EBITDA	2,731	3,129	4,376	5,126	5,926
Adj. PAT	1,406	1,670	2,360	2,812	3,330
Adj. EPS (Rs)	11.5	13.7	19.4	23.1	27.3
EBITDA margin (%)	12.0	11.6	11.7	12.1	12.3
EBITDA growth (%)	19.5	14.6	39.9	17.1	15.6
Adj. EPS growth (%)	22.3	18.8	41.3	19.2	18.4
RoE (%)	18.1	17.9	20.8	20.2	19.6
RoIC (%)	18.8	18.5	21.8	22.2	23.0
P/E (x)	37.4	31.5	22.3	18.7	15.8
EV/EBITDA (x)	19.0	16.9	12.0	10.0	8.3
P/B (x)	6.2	5.2	4.2	3.4	2.8
FCFF yield (%)	2.3	2.1	1.2	2.9	3.7

Source: Company, Emkay Research

Chirag Jainchirag.jain@emkayglobal.com
+91-22-66242428**Jaimin Desai**jaimin.desai@emkayglobal.com
+91-22-66121334**Nandan Pradhan**nandan.pradhan@emkayglobal.com
+91-22-66121238**Marazbaan Dastur**marazbaan.dastur@emkayglobal.com
+91-22-66121281


This report is intended for Nandan Pradhan (nandan.pradhan@emkayglobal.com) use and downloaded at 08/03/2025 11:02 PM

Exhibit 1: Consolidated – Q1FY26 revenue up 44% YoY (also aided by P3L's consolidation for 3M in Q1FY26 vs 2M in Q4FY25); consol EBITDA margin up by 70bps QoQ to 11.1%

Consolidated (Rs mn)	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY %	QoQ %
Revenue	5,372	5,778	5,726	5,842	6,199	6,688	6,338	7,694	8,953	44.4	16.4
Expenditure	4,726	5,114	5,048	5,100	5,394	5,916	5,587	6,893	7,964	47.6	15.5
as % of sales	88.0	88.5	88.2	87.3	87.0	88.5	88.1	89.6	88.9		
Consumption of RM	3,679	3,985	3,893	3,995	4,253	4,679	4,375	5,300	6,241	46.7	17.8
as % of sales	68.5	69.0	68.0	68.4	68.6	70.0	69.0	68.9	69.7		
Employee Cost	611	659	694	663	694	750	779	1,024	1,077	55.1	5.2
as % of sales	11.4	11.4	12.1	11.4	11.2	11.2	12.3	13.3	12.0		
Other expenditure	436	469	461	442	447	487	433	569	646	44.5	13.5
as % of sales	8.1	8.1	8.1	7.6	7.2	7.3	6.8	7.4	7.2		
EBITDA	647	664	678	741	805	772	751	801	990	23.0	23.6
EBITDA margin (%)	12.0	11.5	11.8	12.7	13.0	11.5	11.9	10.4	11.1		
Depreciation	198	211	210	201	203	207	224	264	286	40.9	8.7
EBIT	448	453	468	540	602	566	527	537	703	16.9	31.0
Other Income	28	40	19	44	22	61	40	43	22	3.4	(48.2)
Interest	47	51	47	38	30	27	23	52	64	113.3	23.5
PBT	430	442	441	546	593	600	545	528	661	11.5	25.2
Total Tax	111	110	100	131	138	149	130	179	163	18.1	(9.1)
Adjusted PAT	319	332	340	415	456	451	415	350	499	9.5	42.8
Exceptional Loss/(Gain)	0	0	0	0	0	0	0	0	0		
Reported PAT	319	332	340	415	456	451	415	350	499	9.5	42.8
Adjusted EPS (Rs)	2.6	2.7	2.8	3.4	3.7	3.7	3.4	2.9	4.1	9.5	42.8

(%)	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY bps	QoQ bps
EBITDAM	12.0	11.5	11.8	12.7	13.0	11.5	11.9	10.4	11.1	(193)	65
EBITM	8.3	7.8	8.2	9.2	9.7	8.5	8.3	7.0	7.9	(185)	87
EBTM	8.0	7.7	7.7	9.3	9.6	9.0	8.6	6.9	7.4	(218)	52
PATM	5.9	5.7	5.9	7.1	7.3	6.7	6.5	4.5	5.6	(178)	103
Effective Tax rate	25.8	25.0	22.8	24.0	23.2	24.9	23.9	33.9	24.6	137	(928)

Source: Company, Emkay Research

Exhibit 2: Pricol's core revenue outperformance vs the underlying 2W industry production has accelerated to 11% in Q1 vs 2/3% in Q3/Q4


Source: Company, Emkay Research; Note: Pricol's core revenue growth in Q4FY25 is ex P3L (erstwhile Sundaram Auto Components)

This report is intended for Nandan Pradhan (nandan.pradhan@emkayglobal.com) use and downloaded at 08/03/2025 11:02 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 3: Standalone revenue was up ~12% YoY, with EBITDAM expanding to 115% (up by 110bps QoQ) on improvement across operational parameters

Standalone (Rs mn)	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY(%)	QoQ(%)
Revenue	5,329	5,732	5,686	5,806	6,114	6,638	6,300	6,238	6,829	11.7	9.5
Expenditure	4,743	5,104	5,039	5,055	5,404	5,899	5,611	5,588	6,045	11.9	8.2
as % of sales	88.3	88.3	88.0	86.5	87.2	88.2	88.5	72.6	67.5		
Consumption of RM	3,747	4,009	3,941	4,069	4,321	4,744	4,457	4,347	4,825	11.7	11.0
as % of sales	69.8	69.4	68.8	69.7	69.7	70.9	70.3	56.5	53.9		
Employee Cost	596	642	676	647	675	729	759	816	792	17.3	(3.0)
as % of sales	11.1	11.1	11.8	11.1	10.9	10.9	12.0	10.6	8.8		
Other expenditure	400	453	422	338	407	427	395	425	429	5.3	0.8
as % of sales	7.4	7.8	7.4	5.8	6.6	6.4	6.2	5.5	4.8		
EBITDA	586	629	647	752	710	739	689	649	784	10.4	20.7
EBITDA margin (%)	11.0	11.0	11.4	12.9	11.6	11.1	10.9	10.4	11.5		
Depreciation	194	208	206	195	198	201	219	219	226	14.4	3.2
EBIT	392	421	441	556	513	538	470	430	558	8.8	29.7
Other Income	25	36	12	32	13	57	32	32	15	17.1	(54.2)
Interest	46	51	47	38	30	27	22	34	40	34.6	17.3
PBT	370	406	406	550	495	568	479	428	532	7.5	24.4
Total Tax	103	109	96	116	131	144	123	148	140	7.0	(5.2)
Adjusted PAT	267	297	310	435	364	425	356	280	392	7.6	40.0
Exceptional Loss/(Gain)	0	0	0	0	0	0	0	0	0		
Reported PAT	267	297	310	435	364	425	356	280	392	7.6	40.0
Adjusted EPS (Rs)	2.2	2.4	2.5	3.6	3.0	3.5	2.9	2.3	3.2	7.6	40.0
(%)	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY(bps)	QoQ(bps)
EBITDAM	11.0	11.0	11.4	12.9	11.6	11.1	10.9	10.4	11.5	(14)	107
EBITM	7.3	7.3	7.7	9.6	8.4	8.1	7.5	6.9	8.2	(22)	127
EBTM	6.9	7.1	7.1	9.5	8.1	8.6	7.6	6.9	7.8	(31)	93
PATM	5.0	5.2	5.4	7.5	6.0	6.4	5.7	4.5	5.7	(22)	125
Effective Tax rate	27.7	26.8	23.7	21.0	26.5	25.3	25.7	34.6	26.4	(10)	(822)

Source: Company, Emkay Research

Exhibit 4: Pricol's core EBITDA/PAT margin showed improvement in Q1, aided by multiple cost optimization initiatives undertaken at Pricol

Particulars (Rs mn)	Q1FY25	Q1FY26	YoY %	Q4FY25	QoQ %	Comments
Pricol - Total Revenue	6,199	8,953	44.4	7,694	16	Actuals for Pricol as reported
Less: P3L	0	2,050		1,404	46	Q1FY26 revenue is per earnings call; Q4FY25
Pricol - Core revenue (ex-P3L)	6,199	6,903	11.4	6,290	10	

Particulars (Rs mn)	Q1FY25	Q1FY26	Margin %	Q4FY25	Margin %	Comments
Pricol - Total EBITDA	805	990	11.1	801	10.4	Actuals for Pricol as reported
Less: P3L		144	7.0	77	5.5	P3L Q1FY26 EBITDA is per earnings call
Pricol - Core EBITDA (ex-P3L)	805	846	12.3	723	11.5	

Particulars (Rs mn)	Q1FY25	Q1FY26	Margin %	Q4FY25	Margin %	Comments
Pricol - Total PAT	456	499	5.6	350	4.5	Actuals for Pricol as reported
Less: P3L		51	2.5	12	0.9	Assumed similar 1.5% improvement in PAT over Q4FY25
Pricol - Core PAT (ex-P3L)	456	448	6.5	337	5.4	PAT for Pricol's core business, basis our calculation

Source: Company, Emkay Research; Note: P3L is erstwhile Sundaram Auto Components

Exhibit 5: Margin Analysis – Pricol's consolidated EBITDA/PAT saw a major decline in Q4FY25


Consolidated (%)	Q1FY26	Q1FY25	YoY (bps)	Q4FY25	QoQ (bps)	Comments
Raw material costs	69.7	68.6	110	68.9	82	RM costs saw a QoQ increase led by forex headwinds
Staff costs	12.0	11.2	83	13.3	(128)	Absolute Staff costs were flattish YoY
Other expenses	7.2	7.2	0	7.4	(18)	Multiple cost optimization efforts led to controlled costs
EBITDA	11.1	13.0	(193)	10.4	65	Underlying core business margin also improved, to 12.3%; P3L's margin at 7% vs 5% in 2MFY25
Adjusted net profit	5.6	7.3	(178)	4.5	103	Adjusted net profit was up QoQ on EBITDA improvement as well as lower tax rate

Source: Company, Emkay Research; Note: P3L is erstwhile Sundaram Auto Components

Exhibit 6: Pricol has recently acquired SACL and entered into a technology license agreement (TLA) with Italy-based Domino SRL, to strategically expand into newer products and fortify its market positioning in 2Ws

Entity name	Type	Date	Rationale	Management commentary
Sundaram Auto Components (SACL)	Acquisition	Feb-25	Expand injection molding business; strengthen automotive sector leadership	With this acquisition, our focus will remain on harnessing the combined potential of Pricol and SACL, to become an integrated solution player, driving innovation, and delivering sustainable growth - Vikram Mohan, MD "This partnership is more than a product collaboration—it reflects our broader vision of becoming a key player in handlebar component systems alongside our established Driver Information Systems. With this move, we are reinforcing our position in the two-wheeler ecosystem and deepening our technological capabilities" - Siddharth Manoharan, Director Strategy
DOMINO SRL (Italy)	Technology License	Jun-25	Expand into advanced 2W handlebar control technologies for India and Southeast Asian	"Their legacy of innovation in motorcycle control systems perfectly complements our deep market understanding and manufacturing strength... This collaboration is a shared commitment to deliver greater value and accelerating our growth across new product offerings" - Vikram Mohan, MD

Source: Company, Emkay Research

Exhibit 7: Acquisition of SACL has enabled further expansion of Pricol's already diverse product portfolio

Source: Company, Emkay Research

Exhibit 8: Pricol has launched multiple products in the DIS segment, across end-user segments and customers

Q1 FY26 Product Launch

Bajaj
(RE & Maxima)



Q1 FY26 Product Launch

Bajaj
(Chetak)



LCD TYPE - DIS

Q1 FY26 Product Launch

TVSM
(iQube)



TFT TYPE - DIS

Q1 FY26 Product Launch

Force Motors
(T3 CNG)



LCD TYPE - DIS

Q1 FY26 Product Launch

TATA Motors
(Altroz Facelift & CNG)



LCD TYPE - DIS

Q1 FY26 Product Launch

TATA Hitachi
(Backhoe Loader Shinrai Pro)



Source: Company, Emkay Research

Exhibit 9: We expect Pricol's blended EBITDA margins to improve to 11.7%/12.1%/12.3% by FY26E/FY27E/FY28E

Revenue (Rs mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E	Management Commentary during the Earnings Call
Pricol ex-P3L	19,586	22,718	25,446	28,654	32,567	37,202	
Sundaram	-	-	1,474	8,845	9,729	10,897	
Consolidated	19,586	22,718	26,919	37,499	42,296	48,099	
Growth YoY (%)	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Pricol ex-P3L		16.0	12.0	12.6	13.7	14.2	Expects to continue outpacing the underlying industry on Premiumization-led content growth
P3L					10.0	12.0	Leveraging Pricol's large clientele to add business for P3L; multiple RFQs are being floated
Mix (%)	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Pricol ex-P3L	100	100	95	76	77	77	
Sundaram	-	-	5	24	23	23	
EBITDA (Rs mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Pricol ex-P3L	2,285	2,731	3,052	3,668	4,207	4,866	
P3L			77	708	919	1,060	FY25 EBITDA 2M consolidation based on actual numbers
EBITDAM (%)	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Pricol ex-P3L	11.7	12.0	12.0	12.8	12.9	13.1	Pricol core FY25 margin after removing impact of P3L from Revenue and EBITDA; Pricol aims to revert to 12.5-13% EBITDA
P3L	6.9	8.1	5.2	8.0	9.5	9.7	EBITDA was ~7% for Full year (5.2% for consolidation period); build in steady expansion led by multiple cost optimization
Blended EBITDAM (%)			11.6	11.7	12.1	12.3	
PAT (Rs mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Pricol ex-P3L	1,150	1,406	1,658	2,081	2,488	2,976	
P3L			12	279	324	355	2M PAT for the consolidation Period as per actuals
PAT (%)	FY23	FY24	FY25	FY26E	FY27E	FY28E	
Pricol ex-P3L	5.9	6.2	6.5	7.3	7.6	8.0	
P3L	2.0	2.5	0.8	3.2	3.3	3.3	PAT for 2M of consolidation as per actuals; FY25 PATM stood at 3.6% as per Q4 earnings call
Blended PATM (%)			6.2	6.3	6.6	6.9	Actual FY25 margin at 6.2%

Source: Company, Emkay Research

Exhibit 10: We build in 21%/24%/26% consolidated revenue/EBITDA/PAT CAGR over FY25-28E

Particulars (Rs mn)	FY23	FY24	FY25	FY26E	FY27E	FY28E
Instrument Cluster (DIS)	12,731	15,902	18,211	21,807	24,920	28,678
Growth YoY (%)		24.9	14.5	19.7	14.3	15.1
2Ws	8,275	10,337	13,522	16,380	18,450	20,892
Growth YoY (%)		24.9	30.8	21.1	12.6	13.2
CVs & Off road	3,819	3,589	3,413	3,794	4,089	4,376
Growth YoY (%)		-6.0	-4.9	11.2	7.8	7.0
PVs	637	991	1,276	1,632	2,381	3,410
Growth YoY (%)		55.7	28.8	27.9	45.9	43.2
ACFMS division	6,855	6,815	7,361	6,847	7,647	8,524
Growth YoY (%)		-0.6	8.0	-7.0	11.7	11.5
Of which disc brakes	0	0	0	360	900	1440
					150.0	60.0
Non-brakes	6,855	6,815	7,361	6,487	6,747	7,084
Growth YoY (%)		-0.6	8.0	-11.9	4.0	5.0
Pricol's Core business revenue	19,586	22,718	25,571	28,654	32,567	37,202
Growth YoY (%)		16.0	12.6	12.1	13.7	14.2
P3L	-	-	1,474	8,845	9,729	10,897
Growth YoY (%)					10.0	12.0
Revenue Mix	FY23	FY24	FY25	FY26E	FY27E	FY28E
Revenue splits (%)						
Instrument Cluster	65.0	70.0	67.6	58.2	58.9	59.6
ACFMS	35.0	30.0	27.3	18.3	18.1	17.7
P3L	0.0	0.0	5.5	23.6	23.0	22.7
Within Instrument Cluster Division						
2Ws	65	65	74	75	74	73
CVs & Off road	30	30	19	17	16	15
PVs	5	5	7	7	10	12
Total Consolidated Revenues	19,586	22,718	26,919	37,499	42,296	48,099
Growth YoY (%)	26.8	16.0	18.5	39.3	12.8	13.7
EBITDA	2,285	2,731	3,129	4,376	5,126	5,926
Growth YoY (%)	26.5	19.5	14.6	39.9	17.1	15.6
EBITDA margin (%)	11.7	12.0	11.6	11.7	12.1	12.3
Pricol's Core EBITDA	2,285	2,731	3,052	3,668	4,207	4,866
Pricol's Core-EBITDAM (%)	11.7	12.0	12.0	12.8	12.9	13.1
P3L's EBITDA			77	708	919	1,060
P3L's EBITDAM (%)			5.2	8.0	9.5	9.7
PAT	1,150	1,406	1,670	2,360	2,812	3,330
PAT margin (%)	5.9	6.2	6.2	6.3	6.6	6.9
Pricol's Core PAT	1,150	1,406	1,658	2,081	2,488	2,976
Pricol's Core-PATM (%)	5.9	6.2	6.5	7.3	7.6	8.0
P3L's PAT			12	279	324	355
P3L's PATM (%)			0.8	3.2	3.3	3.3
EPS (Rs.)	9.4	11.5	13.7	19.4	23.1	27.3

Source: Company, Emkay Research; Note: P3L is erstwhile Sundaram Auto Components; P3L has been consolidated for 2 months (Feb-Mar '25)

Exhibit 11: Our FY26/27 estimates remain unchanged; we introduce FY28 estimates

Consolidated (Rs mn)	FY25			FY26E			FY27E			FY28E		
	Actual	%YoY	Earlier	Revised	%Change	%YoY	Earlier	Revised	%Change	%YoY Introduced	% YoY	
Net Sales	26,919	18.5	37,463	37,499	0.1	39.3	42,302	42,296	(0.0)	12.8	48,099	13.7
EBITDA	3,129	14.6	4,372	4,376	0.1	39.9	5,127	5,126	(0.0)	17.1	5,926	15.6
Margin (%)	11.6	(40)bps	11.7	11.7	0bps	5bps	12.1	12.1	0bps	45bps	12.3	20 bps
APAT	1,670	18.8	2,356	2,360	0.1	41.3	2,812	2,812	(0.0)	19.2	3,330	18.4
Margin (%)	6.2	2bps	6.3	6.3	0bps	9bps	6.6	6.6	(0)bps	36bps	6.9	28 bps
EPS (Rs)	13.7	18.8	19.3	19.4	0.1	41.3	23.1	23.1	(0.0)	19.2	27.3	18.4
Pricol's Core business	FY25			FY26E			FY27E			FY28E		
	Actual	%YoY	Earlier	Revised	%Change	%YoY	Earlier	Revised	%Change	%YoY Introduced	% YoY	
Net Sales	25,446	12.0	28,618	28,654	0.1	12.6	32,573	32,567	(0.0)	13.7	37,202	14.2
EBITDA	3,052	11.8	3,663	3,668	0.1	20.2	4,208	4,207	(0.0)	14.7	4,866	15.7
Margin (%)	12.0	(3)bps	12.8	12.8	(0)bps	81bps	12.9	12.9	0bps	12bps	13.1	16 bps
APAT	1,658	17.9	2,077	2,081	0.2	25.5	2,491	2,488	(0.1)	19.6	2,976	19.6
Margin (%)	6.5	33bps	7.3	7.3	0bps	74bps	7.6	7.6	(1)bps	38bps	8.0	36 bps
EPS (Rs)	13.6	17.9	17.0	17.1	0.2	25.5	20.4	20.4	(0.1)	19.6	24.4	19.6
P3L (Rs mn)	FY25			FY26E			FY27E			FY28E		
	2M	12M	Earlier	Revised	%Change	%YoY	Earlier	Revised	%Change	%YoY Introduced	% YoY	
Net Sales	1,474	8,423	8,845	8,845	0.0	5.0	9,729	9,729	0.0	10.0	10,897	12.0
EBITDA	77	590	708	708	0.0	20.0	919	919	0.0	29.8	1,060	15.3
Margin (%)	5.2	7.0	8.0	8.0	0bps	100bps	9.5	9.5	0bps	144bps	9.7	28 bps
APAT	12	299	279	279	0.0	(6.9)	324	324	0.0	16.2	355	9.6
Margin (%)	0.8	3.6	3.2	3.2	0bps	(40)bps	3.3	3.3	2bps	18bps	3.3	(7) bps
EPS (Rs)	0.1	2.5	2.3	2.3	0.0	(6.9)	2.7	2.7	0.0	16.2	2.9	9.6

Source: Company, Emkay Research, Note: P3L is erstwhile Sundaram Auto Components; P3L has been consolidated for 2 months (Feb-Mar '25)

Pricol: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	22,718	26,919	37,499	42,296	48,099
Revenue growth (%)	16.0	18.5	39.3	12.8	13.7
EBITDA	2,731	3,129	4,376	5,126	5,926
EBITDA growth (%)	19.5	14.6	39.9	17.1	15.6
Depreciation & Amortization	821	898	1,142	1,317	1,492
EBIT	1,910	2,232	3,234	3,810	4,434
EBIT growth (%)	26.8	16.8	44.9	17.8	16.4
Other operating income	-	-	-	-	-
Other income	132	166	175	183	202
Financial expense	183	132	208	178	118
PBT	1,859	2,266	3,201	3,815	4,518
Extraordinary items	0	0	0	0	0
Taxes	453	596	842	1,003	1,188
Minority interest	0	0	0	0	0
Income from JV/Associates	0	0	0	0	0
Reported PAT	1,406	1,670	2,360	2,812	3,330
PAT growth (%)	12.8	18.8	41.3	19.2	18.4
Adjusted PAT	1,406	1,670	2,360	2,812	3,330
Diluted EPS (Rs)	11.5	13.7	19.4	23.1	27.3
Diluted EPS growth (%)	22.3	18.8	41.3	19.2	18.4
DPS (Rs)	0	0	0	0	0
Dividend payout (%)	0	0	0	0	0
EBITDA margin (%)	12.0	11.6	11.7	12.1	12.3
EBIT margin (%)	8.4	8.3	8.6	9.0	9.2
Effective tax rate (%)	24.4	26.3	26.3	26.3	26.3
NOPLAT (pre-IndAS)	1,445	1,645	2,384	2,808	3,268
Shares outstanding (mn)	122	122	122	122	122

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	122	122	122	122	122
Reserves & Surplus	8,331	10,038	12,398	15,210	18,540
Net worth	8,453	10,160	12,520	15,332	18,662
Minority interests	0	0	0	0	0
Non-current liab. & prov.	348	301	301	301	301
Total debt	609	1,347	2,120	1,120	1,020
Total liabilities & equity	9,410	11,809	14,941	16,753	19,983
Net tangible fixed assets	4,063	6,612	7,971	9,154	0
Net intangible assets	1,380	1,316	1,316	1,316	0
Net ROU assets	-	-	-	-	-
Capital WIP	383	704	704	704	704
Goodwill	596	517	517	517	517
Investments [JV/Associates]	12	71	71	71	71
Cash & equivalents	1,188	1,090	2,257	2,578	4,163
Current assets (ex-cash)	6,457	8,920	12,100	13,576	15,360
Current Liab. & Prov.	4,946	7,685	10,259	11,427	12,575
NWC (ex-cash)	1,511	1,235	1,841	2,149	2,785
Total assets	9,410	11,809	14,941	16,753	19,983
Net debt	(579)	257	(138)	(1,458)	(3,144)
Capital employed	9,410	11,809	14,941	16,753	19,983
Invested capital	7,827	9,944	11,908	13,400	15,045
BVPS (Rs)	69.3	83.3	102.7	125.8	153.1
Net Debt/Equity (x)	(0.1)	-	-	(0.1)	(0.2)
Net Debt/EBITDA (x)	(0.2)	0.1	-	(0.3)	(0.5)
Interest coverage (x)	11.2	18.2	16.4	22.4	39.4
RoCE (%)	23.7	23.3	26.1	25.7	25.7

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	1,859	2,266	3,201	3,815	4,518
Others (non-cash items)	49	(38)	0	0	0
Taxes paid	(381)	(567)	(842)	(1,003)	(1,188)
Change in NWC	43	437	(606)	(308)	(636)
Operating cash flow	2,548	3,093	3,103	3,998	4,303
Capital expenditure	(1,376)	(1,966)	(2,500)	(2,500)	(2,500)
Acquisition of business	-	-	-	-	-
Interest & dividend income	20	36	0	0	0
Investing cash flow	(1,313)	(3,805)	(2,500)	(2,500)	(2,500)
Equity raised/(repaid)	-	0	0	0	0
Debt raised/(repaid)	(428)	695	773	(1,000)	(100)
Payment of lease liabilities	(78)	0	0	0	0
Interest paid	(182)	(133)	(208)	(178)	(118)
Dividend paid (incl tax)	0	0	0	0	0
Others	-	0	0	0	0
Financing cash flow	(689)	562	565	(1,178)	(218)
Net chg in Cash	565	(114)	1,168	320	1,586
OCF	2,548	3,093	3,103	3,998	4,303
Adj. OCF (w/o NWC chg.)	2,505	2,656	3,709	4,307	4,940
FCFF	1,172	1,127	603	1,498	1,803
FCFE	1,010	1,031	395	1,320	1,686
OCF/EBITDA (%)	93.3	98.8	70.9	78.0	72.6
FCFE/PAT (%)	71.8	61.7	16.7	47.0	50.6
FCFF/NOPLAT (%)	81.1	68.5	25.3	53.4	55.2

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	37.4	31.5	22.3	18.7	15.8
P/CE(x)	23.6	20.5	15.0	12.7	10.9
P/B (x)	6.2	5.2	4.2	3.4	2.8
EV/Sales (x)	2.3	2.0	1.4	1.2	1.0
EV/EBITDA (x)	19.0	16.9	12.0	10.0	8.3
EV/EBIT(x)	27.2	23.7	16.2	13.4	11.1
EV/IC (x)	6.6	5.3	4.4	3.8	3.3
FCFF yield (%)	2.3	2.1	1.2	2.9	3.7
FCFE yield (%)	1.9	2.0	0.8	2.5	3.2
Dividend yield (%)	0	0	0	0	0
DuPont-RoE split					
Net profit margin (%)	6.2	6.2	6.3	6.6	6.9
Total asset turnover (x)	2.5	2.5	2.8	2.7	2.6
Assets/Equity (x)	1.2	1.1	1.2	1.1	1.1
RoE (%)	18.1	17.9	20.8	20.2	19.6
DuPont-RoIC					
NOPLAT margin (%)	6.4	6.1	6.4	6.6	6.8
IC turnover (x)	3.0	3.0	3.4	3.3	3.4
RoIC (%)	18.8	18.5	21.8	22.2	23.0
Operating metrics					
Core NWC days	24.3	16.7	17.9	18.5	21.1
Total NWC days	24.3	16.7	17.9	18.5	21.1
Fixed asset turnover	1.9	1.9	2.2	2.2	2.2
Opex-to-revenue (%)	19.5	19.3	18.8	18.4	18.2


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
30-Jun-25	458	575	Buy	Chirag Jain
30-Jun-25	458	575	Buy	Chirag Jain
19-May-25	432	575	Buy	Chirag Jain
19-May-25	432	575	Buy	Chirag Jain
16-Apr-25	444	575	Buy	Chirag Jain
16-Apr-25	444	575	Buy	Chirag Jain
21-Mar-25	449	575	Buy	Chirag Jain
21-Mar-25	449	575	Buy	Chirag Jain
31-Jan-25	505	600	Buy	Chirag Jain
31-Jan-25	505	600	Buy	Chirag Jain
10-Jan-25	559	650	Buy	Chirag Jain
10-Jan-25	559	650	Buy	Chirag Jain

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 03, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of August 03, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 03, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.